Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc.verified

SYRS

Price:

$1.95

Market Cap:

$52.28M

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced sol...[Read more]

Industry

Biotechnology

IPO Date

2016-06-30

Stock Exchange

NASDAQ

Ticker

SYRS

The ROE as of October 2024 (TTM) for Syros Pharmaceuticals, Inc. (SYRS) is -853.34%

According to Syros Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -853.34%. This represents a change of 2.11% compared to the average of -38.60% of the last 4 quarters.

Syros Pharmaceuticals, Inc. (SYRS) Historical ROE (quarterly & annually)

How has SYRS ROE performed in the past?

The mean historical ROE of Syros Pharmaceuticals, Inc. over the last ten years is -165.36%. The current -853.34% ROE has changed 416.06% with respect to the historical average. Over the past ten years (40 quarters), SYRS's ROE was at its highest in in the June 2024 quarter at 367.24%. The ROE was at its lowest in in the December 2023 quarter at -386.41%.

Quarterly (TTM)
Annual

Average

-165.36%

Median

-85.13%

Minimum

-987.72%

Maximum

-22.30%

Syros Pharmaceuticals, Inc. (SYRS) ROE by Quarter and Year

Discovering the peaks and valleys of Syros Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 2.46%

Maximum Annual ROE = -22.30%

Minimum Annual Increase = -90.43%

Minimum Annual ROE = -987.72%

Quarterly (TTM)
Annual
YearROEChange
2023-987.72%2.46%
2022-38.60%-63.64%
2021-106.16%12.00%
2020-94.78%-0.51%
2019-95.27%20.21%
2018-79.25%-4.15%
2017-82.68%39.58%
2016-59.23%-32.36%
2015-87.57%292.79%
2014-22.30%-90.43%

Syros Pharmaceuticals, Inc. (SYRS) Average ROE

How has SYRS ROE performed in the past?

The current ROE of Syros Pharmaceuticals, Inc. (SYRS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-377.49%

5-year avg

-264.51%

10-year avg

-165.36%

Syros Pharmaceuticals, Inc. (SYRS) ROE vs. Peers

How is SYRS’s ROE compared to its peers?

Syros Pharmaceuticals, Inc.’s ROE is greater than Surrozen, Inc. (-178.66%), greater than Bolt Biotherapeutics, Inc. (-61.40%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Kezar Life Sciences, Inc. (-54.50%), greater than IDEAYA Biosciences, Inc. (-20.53%), greater than Syndax Pharmaceuticals, Inc. (-57.42%), greater than Xencor, Inc. (-28.21%), greater than REGENXBIO Inc. (-68.21%), greater than Crinetics Pharmaceuticals, Inc. (-62.63%), greater than Black Diamond Therapeutics, Inc. (-69.08%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Homology Medicines, Inc. (-100.91%), greater than Harpoon Therapeutics, Inc. (-904.27%), greater than Passage Bio, Inc. (-70.73%), greater than Pasithea Therapeutics Corp. (-74.63%), greater than Kronos Bio, Inc. (-68.82%), greater than Quoin Pharmaceuticals, Ltd. (-112.11%), greater than RenovoRx, Inc. (-403.38%), less than Spero Therapeutics, Inc. (20.70%), less than Coherus BioSciences, Inc. (23.81%), greater than Gracell Biotechnologies Inc. (-37.20%), greater than Neoleukin Therapeutics, Inc. (-47.64%),

Build a custom stock screener for Syros Pharmaceuticals, Inc. (SYRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Syros Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Syros Pharmaceuticals, Inc. (SYRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Syros Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Syros Pharmaceuticals, Inc.'s ROE?

How is the ROE calculated for Syros Pharmaceuticals, Inc. (SYRS)?

What is the highest ROE for Syros Pharmaceuticals, Inc. (SYRS)?

What is the 3-year average ROE for Syros Pharmaceuticals, Inc. (SYRS)?

What is the 5-year average ROE for Syros Pharmaceuticals, Inc. (SYRS)?

How does the current ROE for Syros Pharmaceuticals, Inc. (SYRS) compare to its historical average?